TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$173 Million

Atara Biotherapeutics

Follow-on Offering

Bookrunner, February 2018

Atara Biotherapeutics
Atara Biotherapeutics is developing therapies for patients with severe and life-threatening diseases, with an initial focus on allogeneic T-cell therapies for cancer and autoimmune disease. Atara’s most advanced product candidate, Tab-cel, is an off-the-shelf, allogeneic T-cell immunotherapy for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD), a rare b-cell lymphoma that occurs in immunosuppressed patients after transplant, as well as other EBV associated hematologic and solid tumors. The Company is also advancing two programs in progressive MS, one autologous (ATA190) and one off-the-shelf candidate (ATA188). Additionally, the Company is advancing four next-generation CAR T oncology programs in solid tumors, AML and B-cell malignancies.